Kidney patients get closer to safer dosing of liver drug
NCT ID NCT06397872
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the drug resmetirom (Rezdiffra) is processed in the body of people with severe kidney impairment compared to healthy volunteers. 28 participants took a 100 mg pill once daily for 6 days. The goal was to measure drug levels and safety, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
resmetirom (Rezdiffra)
What this could lead to
If successful, this study could help doctors understand how to safely dose resmetirom in patients with severe kidney problems.
What could go wrong
This is a very early, small study (28 people) focused on drug levels, not on treating disease. It may not lead to any changes in clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Madrigal Research Center
Orlando, Florida, 32809, United States
-
Madrigal Research Center
Tampa, Florida, 33603, United States
-
Madrigal Research Center
Chicago, Illinois, 60643, United States